Acrivon Therapeutics, Inc. is a Pharmaceuticals company based in the United States that is focused on developing oncology medicines tailored to individual patients. With an ESG score of 35.8, the company is considered high risk. Acrivon's pipeline includes the Phase 2 lead program, ACR-368, also known as prexasertib, as well as other preclinical stage pipeline programs targeting DNA Damage Response and cell cycle regulation pathways.